Evidence map›Paper›PMID 33098202›Full record

ArticlePigment cell & melanoma research2021

Model-dependent outcomes: Sex as a biological variable in preclinical mouse models of melanoma.

Gennie L Parkman, David A Kircher, Christopher M Stehn, Martin McMahon, Sheri L Holmen

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Pigment cell & melanoma research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Gennie L ParkmanDepartment of Oncological Sciences, University of Utah Health Sciences Center, Salt Lake City, UT, USA.
David A KircherHuntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT, USA.
Christopher M StehnHuntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT, USA.
Martin McMahonDepartment of Oncological Sciences, University of Utah Health Sciences Center, Salt Lake City, UT, USA.ORCID 0000-0003-2812-1042
Sheri L HolmenDepartment of Oncological Sciences, University of Utah Health Sciences Center, Salt Lake City, UT, USA.ORCID 0000-0002-6411-6032

Funding

Efficacy of combined inhibition of BRAF, MEK, and FAK in melanoma patient derived xenograftsR01CA121118 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Sheri L Holmen · 2007 to 2026
$4.7M
Targeting Oncogenic NRAS, BRAF plus PI3'-Kinase Signaling for Melanoma TherapyR01CA176839 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI MARTIN MCMAHON · 2013 to 2026
$2.9M
Elucidating the Role of PI3K Lipid Effectors in BRAF Mutant MelanomaF31CA254307 · NCI · UNIVERSITY OF UTAH · PI PARKMAN, GENNIE L · 2020 to 2021
$69k
NCI NIH HHS F31 CA254307NCI NIH HHS R01 CA121118NCI NIH HHS R01 CA176839
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Disease Models, AnimalAnimalsFemaleHumansMaleMelanomaMiceMice, KnockoutProto-Oncogene Proteins B-rafPTEN PhosphohydrolaseSex FactorsBraf protein, mouseProto-Oncogene Proteins B-rafPTEN PhosphohydrolasePten protein, mousemelanomamouse modelssex as a biological variable

Identifiers

PMID33098202
PMCPMC8052264

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.